Treatment of autoimmune disorders with oral interferon
AssigneeThe Texas A&M University System
InventorJoseph M. Cummins
Life of this patent
Estimating the term…
Abstract
Autoimmune disorders are treated by the administration of human interferon, particularly IFN-.alpha. or IFN-.beta., at a dosage of from about 0.01 to about 5 IU/lb./day such that the interferon is held in contact with the patient's oral and pharyngeal mucosae. The interferon is administered in a solid dosage form, e.g., a saliva-dissolvable lozenge.
Claims18
A method for treating a human patient afflicted with an autoimmune disorder characterized by chronic inflammatory tissue degeneration, the method consisting essentially of the steps of:
- introducing a saliva-soluble dosage form of interferon into the mouth of the patient,
- allowing the solid dosage form to dissolve in the mouth to form an interferon-containing solution, and
- contacting the interferon-containing solution with the oral and pharyngeal mucosa;
- wherein the interferon is administered to the patient in an amount of about 0.01 to about 5 IU interferon per pound of patient body weight per day.
A method for treating a human patient afflicted with an autoimmune disorder characterized by chronic inflammatory tissue degeneration, the method comprising the steps of:
- introducing a saliva-soluble dosage form of interferon into the mouth of the patient,
- allowing the solid dosage form to dissolve in the mouth to form an interferon-containing solution, and
- contacting the interferon-containing solution with the oral and pharyngeal mucosa;
- wherein the interferon is administered to the patient in an amount of about 0.01 to about 5 IU interferon per pound of patient body weight per day.
Dependencies are inferred from the claim text.